Browse FCRL2

Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF13895 Immunoglobulin domain
Function

May have an regulatory role in normal and neoplastic B cell development.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0005070 SH3/SH2 adaptor activity
GO:0030674 protein binding, bridging
GO:0035591 signaling adaptor activity
GO:0060090 binding, bridging
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCRL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCRL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCRL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2050.622
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9870.171
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3750.519
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.030.966
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3910.758
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4170.76
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.410.0903
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6630.179
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.2590.355
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5740.236
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9040.167
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.260.479
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCRL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCRL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCRL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCRL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCRL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCRL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCRL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCRL2
NameFc receptor-like 2
Aliases FCRH2; IRTA4; CD307b; SH2 domain-containing phosphatase anchor protein 1; IFGP4; SPAP1A; SPAP1B; SPAP1C; IFG ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCRL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.